SCHEMBL2962801

SCHEMBL2962801

COC(=O)CCc1cc(C(=O)c2ccc(OC3CCCC3)cc2O)ccc1OCc1csc2c(C(=O)OC)cccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JUN P05412 1/20 0.51
UGT1A1 P22309 1/20 0.51
UGT1A3 P35503 1/20 0.51
UGT1A8 Q9HAW9 1/20 0.51
PDE5A O76074 2/20 0.36
ALDH1A1 P00352 4/20 0.33
MAPT P10636 2/20 0.33
HTT P42858 2/20 0.33
LMNA P02545 1/20 0.33
PPARG P37231 4/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
MTNR1A P48039 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
PDE4D Q08499 2/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
NPC1 O15118 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3047538 0.87 JUN (0.59) JUNUGT1A1UGT1A3UGT1A8PDE5A
SCHEMBL2960899 0.85 JUN (0.59) JUNUGT1A1UGT1A3UGT1A8PDE5A
SCHEMBL6829363 0.84 JUN (0.60) JUNUGT1A1UGT1A3UGT1A8PDE5A
SCHEMBL2963266 0.84 JUN (0.60) JUNUGT1A1UGT1A3UGT1A8PDE5A
SCHEMBL2963264 0.81 JUN (0.59) JUNUGT1A1UGT1A3UGT1A8PDE5A
SCHEMBL2970244 0.79 JUN (0.57) JUNUGT1A1UGT1A3UGT1A8MTNR1A
SCHEMBL2967003 0.79 JUN (0.57) JUNUGT1A1UGT1A3UGT1A8PDE5A
SCHEMBL1100403 0.78 JUN (0.52) JUNUGT1A1UGT1A3UGT1A8PDE5A
SCHEMBL2962824 0.77 JUN (0.56) JUNUGT1A1UGT1A3UGT1A8MTNR1A
SCHEMBL2967715 0.77 JUN (0.59) JUNUGT1A1UGT1A3UGT1A8PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1445249-B1 NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-07 EP disclosed
US-7772285-B2 Benzophenone derivatives or salts thereof TOYAMA CHEMICAL CO., LTD. (JP) 2010-08-10 US disclosed
US-20050113400-A1 Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo SHUNICHI SHIOZAWA (JP) 2005-05-26 US disclosed
EP-1445249-A1 NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2004-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113400-A1 Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo SP1, AP1G1, JUN JUN 3/4885UGT1A1 1244/4885UGT1A3 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.